EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Evaluation of Oral Nano-Silymarin Formulation Efficacy in the Prevention of Hand-Foot Syndrome and Neuropathy Induced by XELOX or m-FOLFOX6 Regimens in Metastatic Colorectal Cancer: A Triple-Blinded, Randomized Clinical Trial

Hedyieh Karbasforooshan, Hossein Rahimi, Omid Arasteh iD, Abolghasem Allahyari iD, Mehdi Varmaghani, Mahdi Jannati, Vahid Ghavami iD, Mahmoodreza Jaafari iD, Sepideh Elyasi iD

Iranian Journal of Pharmaceutical Research · 16.12.2024 · 23 (1)

DOI: 10.5812/ijpr-152364 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Iranian Journal of Pharmaceutical Research, online erschienen am 16.12.2024. Verfasst von Hedyieh Karbasforooshan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Folinic acid, fluorouracil, and oxaliplatin (FOLFOX) and oxaliplatin and capecitabine (XELOX) are the most widely used chemotherapy regimens for treating metastatic colorectal carcinoma (CRC). These regimens are associated with various adverse reactions, including neuropathy and hand-foot syndrome (HFS). Silymarin, a flavonoid derived from Silybum marianum, has a wide range of biological activities. It has been used to counteract chemotherapy side effects due to its antioxidant, anti-apoptotic, and anti-inflammatory properties.

Objectives

The purpose of this study was to assess the preventive effect of nano-silymarin on neuropathy and HFS induced by the FOLFOX6 and XELOX regimens.

Methods

A randomized, triple-blinded, placebo-controlled clinical trial was conducted on 60 patients who were randomly assigned to receive 70 mg capsules containing 15% silymarin nano micelles twice a day after meals, starting from the first day of the first chemotherapy course and continuing for six courses of the XELOX or m-FOLFOX6 regimen. The severity of adverse effects was assessed after the third and sixth courses based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.

Results

The median CTCAE scores for HFS and neuropathy were significantly lower in the nano-silymarin group at the end of the third course (P < 0.001). However, the difference remained significant only for HFS at the end of the sixth course (P = 0.022). Additionally, the scores increased significantly in both the placebo and nano-silymarin groups during the therapy (P < 0.05).

Conclusions

Nano-silymarin may be considered an adjuvant medication for the prevention of certain chemotherapy-induced adverse reactions. Further research with larger sample sizes and various doses of nano-silymarin is recommended for a more comprehensive evaluation.

Schlagwörter

Stichwörter der Autor:innen

Hand-Foot SyndromeMetastatic Colorectal CancerNano-SilymarinNeuropathyXELOXm-FOLFOX6

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Internal Medicine, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Hematology-Oncology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Management Sciences and Health Economics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Epidemiology and Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.

ORCID-Profile: Omid Arasteh, Abolghasem Allahyari, Vahid Ghavami, Mahmoodreza Jaafari, Sepideh Elyasi

Zitieren

APA

Karbasforooshan, H., Rahimi, H., Arasteh, O., Allahyari, A., Varmaghani, M., Jannati, M., Ghavami, V., Jaafari, M., & Elyasi, S. (2024). Evaluation of Oral Nano-Silymarin Formulation Efficacy in the Prevention of Hand-Foot Syndrome and Neuropathy Induced by XELOX or m-FOLFOX6 Regimens in Metastatic Colorectal Cancer: A Triple-Blinded, Randomized Clinical Trial. Iranian Journal of Pharmaceutical Research, 23(1). https://doi.org/10.5812/ijpr-152364

Vancouver

Karbasforooshan H, Rahimi H, Arasteh O, Allahyari A, Varmaghani M, Jannati M, et al. Evaluation of Oral Nano-Silymarin Formulation Efficacy in the Prevention of Hand-Foot Syndrome and Neuropathy Induced by XELOX or m-FOLFOX6 Regimens in Metastatic Colorectal Cancer: A Triple-Blinded, Randomized Clinical Trial. Iranian Journal of Pharmaceutical Research. 2024;23(1). doi:10.5812/ijpr-152364

BibTeX
@article{Karbasforooshan2024,
  author = {Karbasforooshan, Hedyieh and Rahimi, Hossein and Arasteh, Omid and Allahyari, Abolghasem and Varmaghani, Mehdi and Jannati, Mahdi and Ghavami, Vahid and Jaafari, Mahmoodreza and Elyasi, Sepideh},
  title = {Evaluation of Oral Nano-Silymarin Formulation Efficacy in the Prevention of Hand-Foot Syndrome and Neuropathy Induced by XELOX or m-FOLFOX6 Regimens in Metastatic Colorectal Cancer: A Triple-Blinded, Randomized Clinical Trial},
  journal = {Iranian Journal of Pharmaceutical Research},
  year = {2024},
  volume = {23},
  number = {1},
  doi = {10.5812/ijpr-152364}
}
Kostenlos starten →